0006-5083-01 — Pembrolizumab 790 Mg-berahyaluronid-pmph 9,600 Unit/4.8 Ml Subcut Soln
Cite this view
HANK Price Transparency. (n.d.). PEMBROLIZUMAB 790 MG-BERAHYALURONID-PMPH 9,600 UNIT/4.8 ML SUBCUT SOLN (NDC 0006-5083-01) negotiated rates. PPMan price-transparency data, derived from CMS-required hospital MRFs. Retrieved , from http://ppman.hank.ai/transparency/code/0006-5083-01?code_type=NDC
“PEMBROLIZUMAB 790 MG-BERAHYALURONID-PMPH 9,600 UNIT/4.8 ML SUBCUT SOLN (NDC 0006-5083-01) negotiated rates.” HANK Price Transparency, http://ppman.hank.ai/transparency/code/0006-5083-01?code_type=NDC. Accessed .
“PEMBROLIZUMAB 790 MG-BERAHYALURONID-PMPH 9,600 UNIT/4.8 ML SUBCUT SOLN (NDC 0006-5083-01) negotiated rates,” HANK Price Transparency, accessed , http://ppman.hank.ai/transparency/code/0006-5083-01?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital machine-readable files (45 CFR 180). See methodology.
Usually $47,624–$47,624 (25th–75th percentile) across 1 hospital · 1 payer.
“Negotiated” is the hospital’s negotiated facility rate for this NDC 0006-5083-01 — the consumer-grade median across the country. It covers the facility charge only; the surgeon’s and anesthesiologist’s fees are billed separately.
Per-month price trends are temporarily unavailable while we rebuild them on quality-filtered rates. The medians, percentiles, and per-hospital rates on this page are the quality-filtered figures.
Hospital rates (per row)
Showing consumer-grade rates only. Flagged / outlier filings (excluded from the medians above) are hidden — tick “Show flagged / outlier rates” to include them.
| Hospital | Payer | Plan | Negotiated rate | Gross | Cash | Observed | Source |
|---|---|---|---|---|---|---|---|
| GREATER BALTIMORE MEDICAL CENTER BothFacility | ALL PAYERS | ALL PLANS | $47,623.68 | $47,623.68 | $46,671.21 | 2026-07-01 | MRF ↗ |